Therma Bright Welcomes Medical & Pharmaceutical Veteran Michael Raimondo to Its Advisory Board
Therma Bright Welcomes Medical & Pharmaceutical Veteran Michael Raimondo to Its Advisory Board
New Advisory Board Member Will Initially Focus On Venowave Sales & Business Development
新顧問委員會成員將首先聚焦Venowave銷售和業務拓展
Toronto, Ontario--(Newsfile Corp. - August 13, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce the Company has added Michael Raimondo, a 30-year veteran in sales and operations within the medical and pharmaceutical industries to its advisory board.
加拿大安大略省多倫多,2024年8月13日--(Newsfile Corp. - 2024年8月13日) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma"或「公司」)是領先的診斷和醫療器械技術的開發商和投資合作伙伴之一,公司很高興宣佈已將已經在醫療和製藥行業的銷售和運營進行了30年的Michael Raimondo添加到其顧問委員會。
With more than three (3) decades of experience, Mr. Raimondo brings to the table extensive leadership experience including numerous accomplishments in developing industry-leading strategic account organizations that have delivered customer-centric solutions to healthcare systems across the USA. Mr. Raimondo specializes in sales negotiations, which has successfully led to over $500 million in sales contracts.
Michael Raimondo擁有三十年以上的經驗,具有廣泛的領導和經驗,包括在發展行業領先的戰略帳戶組織方面取得的衆多成就,這些成就爲美國各地的醫療保健系統提供了以患者爲中心的解決方案。Michael Raimondo擅長銷售談判,成功地簽訂了超過5,000萬美元的銷售合同。
Michael is a current Board of Advisor for Marketsmith, one of the country's (US) largest woman-owned and operated independent media and marketing agencies. He also is a Managing Partner of The Potentia Group, which specializes in negotiations training, sales leadership development and consulting within the U.S. healthcare market. Michael has a BS in physics and minor in mathematics from Kutztown University, and has served on the board of the Make A Wish Foundation for the Ohio-Kentucky-Indiana region.
Michael目前是Marketsmith的顧問委員會成員,Marketsmith是美國最大的女性擁有和經營的獨立媒體和營銷機構之一。他還是The Potentia Group的管理合夥人,該公司專門從事美國醫療保健市場內的談判培訓、銷售領導發展和諮詢工作。Michael擁有庫茨敦大學物理學學士學位和數學副修,曾在俄亥俄、肯塔基和印第安納地區的美國願望基金會擔任董事會成員。
"We are pleased that Michael has agreed to join Therma Bright's Advisory Board, where his skills and experience in sales and operations will aid in the Company's sales efforts of its health-tech and med-tech devices, including Venowave," shared Rob Fia, CEO of Therma Bright. "With our Venowave's pending approval on patient reimbursement permanent codes from the U.S. Centers of Medicare and Medicaid (CMS) and a handful of value-added reseller partners ready to engage their medical practitioner networks, we believe Michael will help expand these efforts and open more doors with other reseller partners across the U.S."
"我們很高興Michael同意加入Therma Bright的顧問委員會,在公司的醫療科技和醫療技術設備銷售方面,他在銷售和運營方面的技能和經驗將有助於我們的銷售工作,包括Venowave," Therma Bright的首席執行官Rob Fia分享道。"隨着我們Venowave等待美國醫療保險和醫療補助中心(CMS)對患者費用報銷永久代碼的批准,並有少數增值經銷商合作伙伴準備與其醫療從業人員網絡互動,我們相信Michael將幫助擴大這些努力,並與美國的其他增值經銷商合作伙伴取得更多機會。"
"I am excited to join Therma Bright's Advisory Board, and bring my sales, business development and operations experience to the Company," expressed Michael Raimondo. "With over 30 years of experience in medical and pharmaceutical industries, I am confident in my abilities to help grow the Company's value-added resellers across America to bring new, innovative solutions, like Venowave, to patient suffering from various pains and ailments, such as the 900,000 citizens who suffer from deep vein thrombosis each year per the US CDC."
"我很高興加入Therma Bright的顧問委員會,並將我的銷售,業務發展和運營經驗注入公司," Michael Raimondo表示。"在醫藥行業擁有超過30年的經驗,我對自己在幫助公司增值經銷商推廣全美新的創新解決方案,如Venowave,讓各種疼痛和疾病的患者受益充滿信心,個例如CDC透露每年900,000名公民患有深靜脈血栓形成。"
Mr. Raimondo is taking on his advisory role at Therma Bright with great enthusiasm and has already begun actively tapping into his network to introduce Venowave pre-CMS approval.
Raimondo先生充滿熱情地接受了Therma Bright的顧問角色,並已開始積極利用他的關係網絡,在CMS批准Venowave之前介紹Venowave。
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .
Therma Bright Inc.簡介:Therma Bright是一家開發商和合作夥伴,在各種領先的專有診斷和醫療器械技術方面致力於爲消費者和醫療專業人士提供質量卓越,創新的解決方案,以應對當今最重要的醫療和醫療保健挑戰。在TSXV:THRM,OTCQB:TBRIF,FSE:JNX上交易。訪問:。
Therma Bright Inc.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on Twitter
Rob Fia,首席執行官
rfia@thermabright.com
rfia@thermabright.com
關注我們的Twitter賬號
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events and related information such as future sales of Venowave as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-Looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
前瞻性聲明
本新聞稿中的某些聲明構成"前瞻性"聲明。這些聲明涉及未來事件和相關信息,例如新聞稿中描述的Venowave的未來銷售。所有這些聲明涉及重大的已知和未知的風險、不確定因素和其他因素,這些因素可能導致實際結果與此類前瞻性聲明所表達或暗示的結果不同。前瞻性聲明涉及重大風險和不確定性,不應被視爲未來業績或結果的保證,它們不一定是這些結果的準確指標。由於多種因素和風險的影響,實際結果可能與管理層認爲的合理假設不一致。本新聞稿中包含的前瞻性聲明基於本公司管理層於本新聞稿發佈日所認爲的合理假設,本公司無法保證投資者實際結果將與這些前瞻性聲明一致。本新聞稿中包含的前瞻性聲明是截至本日期的聲明,本公司否認任何意向或義務更新或修訂任何前瞻性聲明,無論是基於新信息、未來事件還是其他因素,除非適用的證券法規要求。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
TSX Venture Exchange及其監管服務提供商(如TSX Venture Exchange政策中所定義)對本新聞稿的充分性或準確性不承擔責任。